a deficit in CoQ10 status has been determined in a number of neuromuscular and neurodegenerative disorders
A secondary loss of CoQ10 status following HMG-Coa reductase inhibitor (statins) treatment has be implicated in the pathophysiology of the myotoxicity associated with this pharmacotherapy
Statin use associated with lower total Testosterone and "non-SHBG bound Testosterone" (i.e. free testosterone) in men. The higher the dose, the lower the trend in Testosterone. The study found decreased testosterone could occur as soon as 1 month.